Integrated DNA Technologies (IDT), a global leader in CRISPR genome editing solutions, inked a licensing agreement with SeQure Dx, a company focused on off...
Nxera Pharma announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neur...
The status is based on preclinical data and data from an ongoing phase 1/2 study for BNT324/DB-1311; preliminary phase 1/2 clinical data showed anti-tu...
Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO) for complex biologics and bioconjugates, andArgonaut...
• Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produ...
Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZenecaand Daiichi S...
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloi...
Partnership to accelerate development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-relat...
Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz P...
AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on smal...
-Logix Biosciences, a biopharmaceutical company focused on the discovery and development of a pipeline of precision therapeutics and companion diagnostic...
The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generat...
EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announ...
© 2025 Biopharma Boardroom. All Rights Reserved.
